Patents Assigned to Synthelabo
  • 1-aminoethylquinoline derivatives for treating urinary incontinence
    Patent number: 6331549
    Abstract: The invention relates to 1-aminoethylquinoline derivatives, to pharmaceutical compositions containing them, to therapeutic methods of using them and to processes for preparing them.
    Type: Grant
    Filed: May 9, 2001
    Date of Patent: December 18, 2001
    Assignee: Sanofi-Synthelabo
    Inventors: Christophe Philippo, Patrick Mougenot, Gérard Defosse, Alain Braun, Philippe Bovy
  • Method of treating a tumor
    Patent number: 6319923
    Abstract: In accordance with the present invention there is provided a method of treating a mammal having a solid tumor, the method comprising: a) administering to the mammal an effective amount of 3-ainino-1,2,4-benzotriazine 1,4-dioxide; b) administering to the mammal an effective amount of paclitaxel; and c) administering to the mammal an effective amount of a platinum complex. The method provides unexpected synergistic efficacy. The invention further provides a kit for treatment of a mammalian tumor comprising 3-amino-1,2,-benzotriazine 1,4-dioxide, paclitaxel and a platinum complex.
    Type: Grant
    Filed: February 16, 2000
    Date of Patent: November 20, 2001
    Assignee: Sanofi-Synthelabo Inc.
    Inventors: Daniel L. Dexter, Paul E. Juniewicz, James B. Rake, Daniel D. Von Hoff
  • N-(arylsulfonyl) amino acid derivatives, process for their preparation and pharmaceutical compositions containing them
    Patent number: 6313120
    Abstract: The invention relates to compounds of formula in which R1 to R9, R16 and R17 are as defined in Claim 1. These compounds are pharmacologically active.
    Type: Grant
    Filed: June 13, 2000
    Date of Patent: November 6, 2001
    Assignee: Sanofi-Synthelabo
    Inventors: Bernard Ferrari, Jean Gougat, Claude Muneaux, Yvette Muneaux, Pierre Perreaut, Claudine Planchenault
  • Cosmetic composition containing a neuropeptide Y receptor antagonist
    Patent number: 6313128
    Abstract: This invention relates to a cosmetic composition containing at least one NPY-antagonist component mixed with an excipient for cosmetic preparations.
    Type: Grant
    Filed: February 9, 2000
    Date of Patent: November 6, 2001
    Assignee: Sanofi-Synthelabo
    Inventors: Elisabeth Blanc-Ferras, Francoise Bono-Colombie, Bernard Breda, Jean Courregelongue, Catherine Ducasse, Remy Mounier, Paul Raymond, Michel Sabadie, Claudine Serradeil-Le-Gal, Vilain Pol, Jean-Marie Pereillo
  • Toothbrush comprising gum-massaging sticks
    Patent number: 6311358
    Abstract: The toothbrush includes a head which is placed at a front longitudinal end of a handle and which is equipped, on an upper face, with a bunch of parallel filaments and a series of rods made from elastomer material which each extend substantially parallel to the filaments and which are placed substantially in two longitudinal rows with one row on each side of the bunch of filaments. Each row of rods includes tall rods which are arranged longitudinally substantially in the center of the row and the length of which is longer than the length of the adjacent filaments and short rods which are arranged at the ends of the row and the length of which is shorter than the length of the adjacent filaments.
    Type: Grant
    Filed: July 26, 2000
    Date of Patent: November 6, 2001
    Assignee: Sanofi-Synthelabo
    Inventors: Lode Soetewey, Lydie Beaugendre
  • Therapeutic use of compounds with &bgr;3-agonist activity
    Patent number: 6310050
    Abstract: The invention relates to the method of use of compounds with B3-agonist activity for inhibiting uterine contractions, preventing or slowing down premature labor, or for the treatment and/or prophylaxis of dysmenorrhea.
    Type: Grant
    Filed: May 24, 2001
    Date of Patent: October 30, 2001
    Assignee: Sanofi-Synthelabo
    Inventors: Charles Advenier, Luciano Manara
  • Oxaliplatin formulations
    Patent number: 6306902
    Abstract: The invention relates to pharmaceutically stable oxaliplatin solution formulations, to the method of use thereof in the treatment of cancer tumors, to processes for the preparation of such formulations, and to a method for stabilizing solutions of oxaliplatin.
    Type: Grant
    Filed: February 22, 1999
    Date of Patent: October 23, 2001
    Assignee: Sanofi-Synthelabo
    Inventors: Nicholas H. Anderson, Ross Blundell, Stephen Brown, David A. England, Martin R. Gray
  • Pharmaceutical formulations in dry form for the oral administration of a cyclic quaternary ammonium compound
    Patent number: 6303626
    Abstract: The pharmaceutical formulations according to the invention contain from 0.5 to 50% by weight of a cyclic quaternary ammonium compound and pharmaceutically appropriate excipients and are formulated by wet granulation, preferably with polysorbate 80.
    Type: Grant
    Filed: July 30, 1999
    Date of Patent: October 16, 2001
    Assignee: Sanofi-Synthelabo
    Inventors: Bernard Abramovici, Xavier Boulenc, Jean-Claude Gautier, Pol Vilain
  • Compounds which are specific antagonists of the human NK3 receptor and their use as medicinal products and diagnostic tools
    Patent number: 6294537
    Abstract: A method for treating diseases which involve interaction of neurokinin B with NK3 receptors in humans. The method comprises administering a therapeutically effective amount of a NK3 antagonist compound having the formula: in which: R1 and R11 together represent a —(CH2)3-group.
    Type: Grant
    Filed: May 7, 1999
    Date of Patent: September 25, 2001
    Assignee: Sanofi-Synthelabo
    Inventors: Daniel Bichon, Patrick Gueule, Didier Van Broeck, Xavier Emonds-Alt, Vincenzo Proietto
  • Human NK3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them
    Patent number: 6291672
    Abstract: Compounds of the formula are useful as human NK3 receptor antagonists.
    Type: Grant
    Filed: November 9, 1999
    Date of Patent: September 18, 2001
    Assignee: Sanofi-Synthelabo
    Inventors: Daniel Bichon, Xavier Emonds-Alt, Patrick Gueule, Vincenzo Proietto, Didier Van Broeck
  • Stable freeze-dried pharmaceutical formulation
    Patent number: 6284277
    Abstract: The subject of the invention is a freeze-dried formulation consisting of an amorphous phase and a crystalline phase, which is pharmaceutically acceptable, comprising at least one nonprotein active ingredient, characterized in that it contains mannitol and alanine in a ratio R of between 0.1 and 1, R representing the mass of mannitol to the mass of alanine.
    Type: Grant
    Filed: December 9, 1998
    Date of Patent: September 4, 2001
    Assignee: Sanofi-Synthelabo
    Inventors: Colette Bouloumie, Thierry Breul, Laurence Colliere, Philippe Faure
  • Type-2 neurotensin receptor (NT-R2)
    Patent number: 6274333
    Abstract: This invention relates to a purified polypeptide which constitutes the type-2 neurotensin receptor (NT-R2), as well as the nucleotide sequence encoding this polypeptide.
    Type: Grant
    Filed: December 28, 1999
    Date of Patent: August 14, 2001
    Assignee: Sanofi-Synthelabo
    Inventors: Daniel Caput, Pascale Chalon, Pascual Ferrara, Natalio Vita
  • Azacycloalkane derivatives, preparation and therapeutic application
    Patent number: 6262060
    Abstract: The invention relates to azacycloalkane derivatives, to pharmaceutical compositions containing them, to processes for preparing them, and to methods for the treatment of hyperglycaemia, diabetes, obesity or inflammation utilizing them.
    Type: Grant
    Filed: November 27, 2000
    Date of Patent: July 17, 2001
    Assignee: Sanofi-Synthelabo
    Inventors: Manuel Bedoya-Zurita, Juan Antonio Diaz Martin, Marc Daumas
  • 4-Oxo-3,5-dihydro-4H-pyridazino[4,5-b]-indole-1-acetamide derivatives, their preparation and their application in therapy
    Patent number: 6262045
    Abstract: Compounds of general formula (I) in which X represents a hydrogen or halogen atom or a methyl, methoxy or phenylmethoxy group, Y represents a hydrogen atom, 1 or 2 halogen atoms or a hydroxyl, methoxy, nitro or methyl group, R1 represents a hydrogen atom or a (C1-C4)alkyl group, R2 and R3 each represent a hydrogen atom, a (C1-C4)alkyl group or a phenylmethyl group or else R2 and R3 form, with the nitrogen atom which carries them, an azetidinyl, pyrrolidinyl, 3-ethoxypyrrolidinyl, piperidinyl, morpholinyl, 4-methylpiperazinyl or 1,3-thiazolidinyl group. Application in therapeutics.
    Type: Grant
    Filed: April 13, 2000
    Date of Patent: July 17, 2001
    Assignee: Sanofi-Synthelabo
    Inventors: Yannick Evanno, Laurent Dubois, Mireille Sevrin, Frank Marguet, Jacques Froissant, Régine Bartsch, Catherine Gille
  • Intermediates and process for the preparation thereof
    Patent number: 6258961
    Abstract: A process for the preparation of 2-[(2-thienyl)-ethylamino]-(2-halogenophenyl)-acetamides of general formula (VII) starting from the nitriles of general formula (I). Compounds of general formula (VII) are valuable intermediates.
    Type: Grant
    Filed: November 12, 1999
    Date of Patent: July 10, 2001
    Assignee: Sanofi-Synthelabo
    Inventors: Mária Bakonyi, Marianna Csatári née Nagy, Erzsébet Molnár née Bakó, Zoltán Makovi, Piroska Jobb, Edit Bai née Tállai
  • 5-aryl-3-(8-azabicyclo[3.2.1]oct-3-yl)-1,3,4-oxadiazol-2(3H)-one derivatives as 5-ht4 receptor ligands
    Patent number: 6255319
    Abstract: Compound of general formula (I) in which R1 represents an alkyl or cycloalkylmethyl group, X1 represents a hydrogen or halogen atom or an alkoxy group, or alternatively OR1 and X1 together represent an —OCH2O—, —O(CH2)2—, —O(CH2)3—, —O(CH2)2O— or —(CH2)3O— group, X2 represents a hydrogen atom or an amino group, X3 represents a hydrogen or halogen atom, and R2 represents a hydrogen atom, an optionally substituted alkyl group, an optionally substituted phenylalkyl group or a group —(CH2)nCO—Z in which n represents a number from 1 to 6 and Z represents a 1-piperidyl group. Therapeutic application.
    Type: Grant
    Filed: October 15, 1999
    Date of Patent: July 3, 2001
    Assignee: Sanofi-Synthelabo
    Inventors: Samir Jegham, Alistair Lochead, Frédéric Galli, Alain Nedelec, Axelle Samson, Thierry Gallet
  • Pyridone derivatives, their preparation and their use as synthesis intermediates
    Patent number: 6252082
    Abstract: The invention concerns compounds of formula (I) in which: R is —NO2 or —NHR3, R3 being hydrogen, —COR4 (R4 selected among (C1-C4) alkyl, aryl and aryl (C1-C4) alkyl, —COOR5 (R5 selected among (C1-C4) alkyl and aryl (C1-C4) alkyl), —CONHR6 or SO2R6 (R6 selected among (C1-C5) alkyl, aryl and aryl(C1-C4) alkyl), —SO2NR7R8 (R7 and R8 independently of each other represent hydrogen or (C1-C4) alkyl or form with the nitrogen atom a morpholine group), aryl (C1-C4) alkyl, R1 is a (C1-C4) alkyl group linear or branched, cyclo (C3-C8) alkyl, aryl optionally substituted, aryl (C1-C4) alkyl optionally substituted, heteroaryl, R2 is a hydrogen atom, a (C1-C4) alkyl or arylmethyl group, X is an oxygen or sulphur atom, a —CH2—, —SO2 or —NR1— group and Y is a hydrogen atom or (C1-C6) alkyl. The invention is applicable to synthesis intermediates.
    Type: Grant
    Filed: July 14, 1999
    Date of Patent: June 26, 2001
    Assignee: Sanofi-Synthelabo
    Inventors: Gilbert Lassalle, Patrice Bellevergue, Jean-Claude Bourbier, Daniel Galtier, Valérie Martin
  • 3-(Pyrrolidin-3-yl)-1,3,4-oxadiazol-2(3H)-one derivatives and their use as 5-HT4 ligands
    Patent number: 6248757
    Abstract: Compounds corresponding to the general formula (I) in which R1 represents hydrogen or an alkyl or cycloalkylmethyl group, X1 represents hydrogen or a halogen or an alkoxy group, or alternatively OR1 and X1 together represent a group of formula —OCH2O—, —O(CH2)2—, —O(CH2)3—, —O(CH2)2O— or —O(CH2)3O—, X2 represents hydrogen, an amino group or a group of general formula —NHCO2R in which R represents an alkyl or phenylalkyl group, X3 represents hydrogen or a halogen, and R2 represents hydrogen or an alkyl, phenylalkyl or [(4-dimethylamino)piperid-1-ylcarbonyl]alkyl group. Therapeutic application.
    Type: Grant
    Filed: November 4, 1999
    Date of Patent: June 19, 2001
    Assignee: Sanofi-Synthelabo
    Inventors: Alistair Lochead, Samir Jegham, Jean Jeunesse
  • Use of sulphonanilide derivatives to obtain a medicine for treating retrograde ejaculation or aspermia
    Patent number: 6248786
    Abstract: Descriptive summary: use of a compound with the formula (I) where R1 is a hydrogen atom, a C1-2 alkyl group, a C1-2 fluoroalkyl group or a C1-2 perfluoroalkyl group and R2, R3 and R4, which may be the same or different, all represent a hydrogen atom, a straight- or branched-chain C1-4 alkyl group or a C3-4 cycloalkyl group, and R5 is a hydrogen atom, a halogen such as fluorine or chlorine, a C1-4 alkyl group or a straight- or branched-chain C1-4 alkoxy group to manufacture a medicinal agent which can be used to treat ejaculation problems such as retrograde ejaculation or aspermia.
    Type: Grant
    Filed: March 22, 2000
    Date of Patent: June 19, 2001
    Assignee: Sanofi-Synthelabo
    Inventors: Itzchak Angel, Denis Martin, Sonia Arbilla
  • Combination of an ADP-receptor blocking antiplatelet drug and antihypertensive drug and a method for preventing a cerebral infarction employing such combination
    Patent number: 6248729
    Abstract: A method is provided for preventing a cerebral infarction by administering to a patient a combination of an ADP-receptor blocking antiplatelet drug, such as clopidogrel, in combination with an antihypertensive agent such as an angiotensin AII antagonist (for example, irbesartan), an ACE inhibitor (for example, fosinopril) or a NEP/ACE inhibitor such as omapatrilat.
    Type: Grant
    Filed: June 9, 1999
    Date of Patent: June 19, 2001
    Assignees: Bristol-Myers Squibb Co., Sanofi-Synthelabo
    Inventors: Anthony A. Coniglio, Francis R. Plat, Melvin S. Blumenthal